IVIEW Collaboration with Dr. Amin Javer at St. Paul’s Hospital and Sinus Centre, University of British Columbia, Canada to study Povidone Iodine formulations including IVIEW-1503, a long-lasting Povidone Iodine nasal spray for the treatment of COVID-19

September 16, 2020

[September 16, 2020, Doylestown, Pennsylvania] – IVIEW Therapeutics Inc., an innovative clinical stage specialty pharmaceutical company is proud to announce that Health Canada has offered Dr. Amin Javer, a renowned rhinologist at the St. Paul’s Sinus Centre, University of British Columbia, Canada, a notification of Authorization for Clinical Trial Application of povidone iodine (PVP-I) formulations, including IVIEW’s long-lasting PVP-I Nasal Spray: IVIEW-1503, for the treatment of COVID-19 patients.

Given the current state of the COVID pandemic, there is a large unmet need for treatments that could decrease infectivity, or decrease progression and morbidity of an infection with COVID-19. To that end, we have developed a gel forming nasal solution with a known antiseptic (Povidone-Iodine) intended to decrease viral load in the nasopharynx and potentially improve the clinical course of COVID-19. IVIEW has collaborated with Dr. Amin Javer since early 2020 for the development of this innovative product for clinical evaluation. IVIEW’s novel PVP-I formulation, IVIEW-1503, has shown promising results of completely eradicating SARS-CoV-2 virus to non-detectable level within 2 minutes against SARS-CoV-2 virus in an in-vitro virucidal assay.[…]

IVIEW announces successful completion of in-vitro virucidal study of IVIEW-1503, a safe, non-toxic and long-lasting Povidone Iodine nasal spray for the prevention and treatment of COVID-19

May 20, 2020

Doylestown, Pennsylvania–IVIEW Therapeutics Inc., an innovative clinical stage specialty pharmaceutical company is proud to announce the successful completion of in-vitro virucidal study of IVIEW-1503, a safe, non-toxic and long-acting Povidone Iodine nasal spray for the prevention and treatment of COVID-19. The result was published on bioRxiv preprint doi: https://doi.org/10.1101/2020.05.18.103184 titled “In-Vivo Toxicity Studies and In-Vitro Inactivation of SARS-CoV-2 by Povidone-iodine In-situ Gel Forming Formulations.”

The rising numbers of COVID-19 cases in the United States earlier this year has prompted IVIEW to develop a safe, non-toxic and long-acting Povidone Iodine nasal spray for the prevention and treatment of the COVID-19 infection to curb the spread of SARS-CoV-2 virus. In collaboration with Institute for Antiviral Research at Utah State University, an in-vitro virucidal assay test with IVIEW’s novel PVP-I formulation, IVIEW-1503, against SARS-CoV-2 virus had showed promising results of completed eradicated SARS-CoV-2 virus to non-detectable level within 2 minutes. Povidone-iodine (PVP-I) is known for its high virucidal efficacy especially against enveloped viruses. […]

IVIEW completed pre-IND meeting with FDA for the development of IVIEW-1501/1502 for the treatment of Chronic Rhinosinusitis (CRS)

April 14, 2020

Doylestown, Pennsylvania –IVIEW Therapeutics Inc., an innovative, clinical-stage biopharmaceutical company committed to becoming a leader in topical drug development with specialization focus on ophthalmology, and otolaryngology, completed a successful pre-IND meeting with FDA to develop IVIEW-1501/1502 (Povidone Iodine in combination of Budesonide Nasal Irrigation and Nasal Spray Compositions) for the treatment of Chronic Rhinosinusitis (CRS).

CRS is the result of mixed inflammatory and infectious processes that concurrently affects the noses and para-nasal sinuses. It is a debilitating disease that can lead to significant physical symptoms and substantial functional impairment. The condition is defined by a constellation of symptoms and prolonged clinical course, affecting as many as 30 million US adults per year. Persistence of infection can lead to chronic mucosal inflammation, altered sinonasal ciliary function, and nasal polyp formation. IVIEW-1501/1502 (Povidone Iodine in combination of Budesonide Nasal Irrigation and Nasal Spray Compositions) addresses the underlying infectious pathology from both planktonic and biofilm sources, and can alleviate the concomitant inflammatory response, with a longer therapeutic effect. This tripartite approach to CRS disease addresses all causative pathways and chemically reduces the host immune response that leads to prolonged disease. […]

iVIEW is developing a safe, non-toxic and long-acting Povidone Iodine nasal spray for the prevention and treatment of COVID-19 infection to curb the COVID-19 spread

April 5, 2020

Doylestown, Pennsylvania – IVIEW Therapeutics Inc., an innovative clinical stage specialty pharmaceutical company that is committed to becoming a leader in topical drug development with specialization in ophthalmology is currently developing treatment and prevention strategies against the novel SARS-CoV-2, also known as, COVID-19.

IVIEW’s unique Povidone-Iodine (PVP-I) formulation has been used as a powerful antiseptic against infections such as Acute Adenoviral Conjunctivitis and Chronic Rhinosinusitis. As the community knows, there is a significant unmet medical need in treating patients affected by COVID-19 and curb the spread of COVID-19 transmission. IVIEW initiated multiple projects to fight this global pandemic. IVIEW hopes to apply their innovative in-situ gel sustain release formulation technology using PVP-I’s broad spectrum anti-microbial, anti-viral, and anti-fungal properties against the novel COVID-19. […]

iView Announces First Patient Treated in Phase 2 Clinical Trial Program Evaluating IVIEW-1201 in Patients with Acute Adenoviral Conjunctivitis

December 19, 2019

Doylestown, Pennsylvania -- Today, iView Therapeutics Inc. announced that the first patient has been treated in the Phase 2 IVIEW-1201-01-AIC clinical trial program accessing the efficacy of IVIEW-1201 for adolescent and adult patients (age ≥15 years) with Acute Adenoviral Conjunctivitis. First subject was dosed on 19 Dec in India at Disha Eye Hospital Pvt. Ltd. Kolkata under this Phase II Clinical trial program. This study was planned in US, India and China simultaneously.

“Acute Infectious Conjunctivitis is the most common and most contagious ocular infections around the world, but there is no approved treatment for the acute viral conjunctivitis, which represents a massive unmet medical need in ophthalmology,” said Bo Liang, Ph.D. MBA, Chairman & President, iView Therapeutic Inc. “IVIEW-1201 is a broad spectrum antiseptic gel forming ophthalmic solution which is potentially effective against all infectious pathogens including bacteria, mycobacteria, fungus and virus. The initiation of the global Phase 2 clinical trial program is an important milestone as we seek to provide an effective treatment option for AVC patients.”[…]

iVIEW-1201 Phase II IND clinical trial application for the Treatment of Adenoviral Conjunctivitis approved by Indian Regulatory Authority (CDSCO)

June 6, 2019

Doylestown, Pennsylvania--iVIEW Therapeutics Inc., an innovative specialty pharmaceutical company committed to becoming a leader in topical drug development with specialization focus on ophthalmology, announced that its Phase II clinical trial IND application of iVIEW-1201 for the Treatment of Adenoviral Conjunctivitis has been approved by Indian Regulatory Authority, CDSCO.

Dr. Bo Liang, Chairman & President of iVIEW and Dr. Vijai Kumar, President & CMO of Excel Life Sciences have attended the Subject Expert Committee (SEC) meeting on 06/Jun’19 at Indian FDA and received positive recommendations from SEC. Excel Life Sciences, iVIEW's partner for conducting studies in India, is expecting the written approval for study from Drug Controller General of India (DCGI) by July. According to Dr. Liang, "we are excited about the fast approval for the study in India and look forward to starting the trial and enrolling patients soon. We believe that iVIEW-1201 will be the first FDQ approved sustained release broad spectrum antiseptic formulation, which will bring significant value to patients as there is no approved treatment for viral conjunctivitis currently. This is an exciting development for iVIEW." Dr. Kumar commented, “We believe Excel expertise in conducting conjunctivititis trials in India will help the successful trial execution of the phase II trials and speed up the process for market approval.”[…]

iVIEW Therapeutics was awarded SBIR Innovative Year 2 Grant by NIH’s National Institute of Allergy and Infectious Diseases (NIAID)

April 11, 2019

Doylestown, Pennsylvania--iVIEW Therapeutics Inc., a clinical-stage biotechnology company focusing on topical drug development on the areas of ophthalmology, otolaryngology, and dermatology, today announced that it has been awarded a Small Business Innovation Research (SBIR) Year 2 Award of $300,000 from National Institute of Allergy and Infectious Diseases (NIAID) at National Institutes of Health (NIH). This phase I SBIR Year 2 grant is awarded based on iVIEW’s successful completion of its Year 1 project since April 1, 2018. iVIEW's project is titled "In-situ gel of Povidone Iodine/Budesonide as Sustained Nasal Drug Delivery for the Treatment of Chronic Rhinosinusitis”. “If successful, this combination of a long acting broad anti-infective with an anti-inflammatory agent is likely to have a significant impact on treatment of patients with chronic rhinosinusitis (CSR)", commented by the NIH reviewers. Dr. Bo Liang, Chairman & President at iVIEW comments, "The continuation of SBIR award showed the confidence of the agency towards our innovation and project progress. In the Grant Year 2 period, we will progress quickly though pre-clinical studies and plan to file US IND in the year of 2020 to move into clinical development."[…]

iVIEW-1201 Phase II IND application for the Treatment of Adenoviral Conjunctivitis Accepted by US FDA

December 31, 2018

Doylestown, Pennsylvania--iVIEW Therapeutics Inc., an innovative specialty pharmaceutical company committed to becoming a leader in topical drug development with specialization focus on ophthalmology, dermatology and otolaryngology, today announced that its Phase II clinical trial IND application of iVIEW-1201 was been accepted by US FDA. As Dr. Wendy Streight, FDA Regulatory Project Manager, said in her email, “just to confirm, yes, your study is safe to proceed.”

In the pre-IND meeting response from FDA, FDA responded “A phase I safety/tolerability study is not needed for this drug product. There is adequate safety data available to proceed with dose ranging/efficacy studies.” Also FDA stated that “A drug vs. placebo pivotal trial for acute viral conjunctivitis is acceptable.”[…]

iVIEW-1201

August 15, 2018

We are currently optimizing our lead ophthalmic drug iVIEW-1201 for the treatment of active infections of the conjunctiva and cornea by bacteria, mycobacteria, virus, fungus, or amoebic causes. The current US ocular antibiotic market is over $1 billion with an additional $500 million untapped viral conjunctivitis market for which there is no FDA approved treatment. This represents a massive unmet medical need in ophthalmology and an enormous market potential.

Acute conjunctivitis (“pink eye”) is one of the most common and most contagious ocular infections seen in the United States, Japan and Europe. Approximately 50 percent of infectious conjunctivitis cases have a viral etiology, and 65 to 90 percent of these are caused by adenovirus. Viral conjunctivitis is highly infectious and transmissible, causing lost work and school days as well as increased healthcare costs and risks from unnecessary antibiotic prescriptions. There are 5.9 million cases of infectious conjunctivitis annually in the United States and approximately 5.4 million cases in the EU annually. […]

iVIEW-1501

August 9, 2018

Pennsylvania Biotechnology Center at Bucks County
3805 Old Easton Road
Doylestown PA 18902 USA
Copyright © 2021 iVIEW Therapeutics, Inc. All rights reserved.